A2 BIO
LIVE

Serial Number

97074028

Owner

A2 Biotherapeutics, Inc.

Attorney

Joi A. White

Filing Date

Oct 14, 2021

Add to watchlist:

No watchlists yet
View on USPTO

A2 BIO Trademark

Serial Number: 97074028

A2 BIO is a trademark filed by A2 Biotherapeutics, Inc. on October 14, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

A2 Biotherapeutics, Inc. (10 trademarks)

Agoura Hills, CA 91301

Entity Type: 03

Trademark Details

Filing Date

October 14, 2021

Registration Date

Not Registered

Published for Opposition

April 4, 2023

Goods & Services

Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of inflammation and inflammatory diseases; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases

Identification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases;

Manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease;

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 2, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 1, 2025 EX1G
SOU EXTENSION 1 FILED
Nov 24, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 24, 2025 EEXT
CORRECTED NOA E-MAILED
Nov 10, 2025 NOAC
DIVISIONAL PROCESSING COMPLETE
Nov 10, 2025 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 7, 2025 AITU
DIVISIONAL REQUEST RECEIVED
May 30, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
May 30, 2025 ERTD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 20, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 20, 2025 EX4G
SOU EXTENSION 4 FILED
May 19, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2024 EXRA
SOU EXTENSION 3 GRANTED
Nov 7, 2024 EX3G
SOU EXTENSION 3 FILED
Nov 7, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 7, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 15, 2024 EXRA
SOU EXTENSION 2 GRANTED
May 14, 2024 EX2G
SOU EXTENSION 2 FILED
May 14, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
May 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 21, 2023 EXRA
SOU EXTENSION 1 GRANTED
Nov 17, 2023 EX1G
SOU EXTENSION 1 FILED
Nov 17, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 17, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 30, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 4, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 4, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 15, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 25, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 22, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 22, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 22, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2022 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2022 REAP
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 4, 2021 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 3, 2021 NWOS
NEW APPLICATION ENTERED
Oct 18, 2021 NWAP